Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

BB Biotech AG closes the 2025 fiscal year with a profit

23.01.2026

Ad hoc announcement pursuant to Art. 53 LR

In accordance with regulations on ad hoc publicity, BB Biotech AG (ISIN CH0038389992) is releasing the following information:

Based on its preliminary unaudited consolidated figures, BB Biotech AG reports a profit of approximately CHF 578 mn for the financial year 2025 (profit of CHF 76 mn in the previous year). For an investment company, the results reflect the share price development of the companies held in the portfolio.

The publication of all relevant portfolio data and the complete annual report will take place on February 20, 2026.

For further information:
Bellevue Asset Management AG
Theaterstrasse 12, 8001 Zurich, Switzerland, Phone +41 44 267 67 00

Head BB Biotech
Dr. Christian Koch

Investor Relations
Rachael Burri

E-Mail: ir@bbbiotech.com
Phone: +41 44 267 67 17

Media Relations
Tanja Chicherio, tch@bellevue.ch